Chimeric antigen receptor (CAR) T cell therapy, an immunotherapy using gene-modified T cells, has recently made a big success. CAR T cells targeting CD19 is highly effective against B cell malignancies. Next good target for CAR T therapy is multiple myeloma. B cell maturation antigen has been proved to be a good target for CAR T cell therapy in early-phase clinical trials. We are also developing CAR T cells targeting a protein conformation that is preferentially detected in myeloma cells. In this review, I will summarize the state of art in the field of CAR T cell therapy against myeloma, and also present our effort to develop a new CAR T cell therapy.
CAR T cell therapy
The idea of chimeric antigen receptor (CAR) T cell therapy CAR T cell therapy actually started from the 1980s. After huge effort by many researchers, CAR T cell therapy is now becoming a practical and highly effective therapy for leukemia and lymphoma patients. CAR is generated by fusing the antigen recognition domain of a tumor-specific monoclonal antibody (mAb) with CD3ζ and a costimulatory molecule such as CD28 or 4-1BB [1] , and transduced into T cells using retro-or lenti-virus to male CAR T cells. CAR T cells recognize the cancer cell surface antigen specifically using mAb-derived antigen-recognition domain, and are activated. Activated CAR T cells kill tumor cells and also proliferate extensively. CAR T cells share the advantages of both mAbs and cytotoxic T cells, and have a high affinity and specificity for tumor cells, as well as high cytotoxicity and proliferation potential ( Fig. 1) .
CD19 CAR T cells showed surprisingly high effectiveness against acute lymphocytic leukemia and malignant lymphoma [2] [3] [4] . As a result, CD19 CAR T cell therapy was approved in the United States by the FDA in 2017, and also in Japan in 2019. Initially, many people in this filed did not believe that CAR T cell therapy would be widely used because of severe cytokine release syndrome (CRS). In the early 2010s, early death after CAR T cell infusion was reported. However, anti-IL6 mAb has made CAR T cell therapy much safer therapy. Anti-IL6 receptor mAb is highly effective against CRS. Importantly, the major source of IL-6 in CRS is macrophages, but not T cells, suggesting that cytotoxic effect of CAR T cells is not impaired upon inhibition of IL6 signaling [5, 6] .
BCMA CAR T cell therapy for multiple myeloma
Multiple myeloma (MM) is one of the most frequent hematological cancers, and is characterized by the aberrant expansion of clonal plasma cells. There have recently been remarkable advances in MM treatment, but the cure of MM is still extremely difficult, and relapsed and refractory MM patients have very poor prognosis. Therefore, new therapeutic modalities for MM is urgently needed. CAR T cell therapy is one of the most promising strategies.
One promising antigen for anti-MM CAR T cell therapy is B cell maturation antigen (BCMA). BCMA is expressed in most of MM cells in many cases. Expression of BCMA in normal tissues is restricted to a subset of B cells, normal plasma cells. Importantly, BCMA expression is not detected in non-hematopoietic tissues, suggesting that on target off tumor toxicity is not a big concern when BCMA is used as a target for CAR T cells. Clinical trials of BCMA CAR T cells have been performed in several institution using different CAR constructs (Table 1) .
Researchers at the National Institutes of Health generated the first anti-BCMA CAR using CD28 as a co-stimulatory molecule [7] . In a phase I study [8, 9] , patients with relapsed/refractory MM were treated with BCMA CAR T cells after pre-conditioning with cyclophosphamide and fludarabine. Sixteen patients received the highest dose of 9 × 10 6 CAR-BCMA T cells/kg. The overall response rate of 16 patients who were infused with the highest dose of 9 × 10 6 BCMA CAR T cells/kg was 81%. Among them, 63% patients exhibiting a very good partial response (VGPR) or complete response. The median event-free survival was 31 weeks. All 11 patients who had an anti-MM response of partial response or better and who had MM evaluable for minimal residual disease (MRD) achieved MRD-negative status in the bone marrow. Severe CRS were in some cases, while all the patients recovered and there were no fatal cases. This study proved that BCMA CAR T cell therapy is effective against relapsed/refractory, poor-prognosis MM.
Researchers in the University of Pennsylvania generated BCMA-targeting CAR T cells using 4-1BB as a co-stimulatory molecule. The CAR T cell product was engineered by lentiviral transduction to express a fully human, BCMAspecific CAR [10] . In the clinical trial, 25 patients comprised 3 cohorts depending on their treatment, as follows:
(1) 1-5 × 10 8 CART-BCMA cells alone; (2) cyclophosphamide (Cy) 1.5 g/m 2 + 1-5 × 10 7 CART-BCMA cells; and (3) Cy 1.5 g/m 2 + 1-5 × 10 8 CART-BCMA cells. The numbers of treated subjects exhibiting responses were 4/9 (44%) in cohort 1, 1/5 (20%) in cohort 2, and 7/11 (64%) in cohort 3; these included 5 partial, 5 very good partial, and 2 complete responses. CRS was observed in 88% of subjects and was ≥ grade 3 in 32%. Three patients (12%) had ≥ grade 3 neurotoxicity. One patient died during the trial after developing grade 4 CRS complicated by candidemia. This study suggests that lympho-depletion prior to BCMA CAR injection is feasible.
Promising results of a multicenter phase I study of bb2121 were recently reported [11] . Bb2121 consists of CAR T cells [12] transduced with a lentiviral vector encoding an anti-BCMA single-chain variable fragment (scFv), a 4-1BB costimulatory motif, and a CD3-ζ T cell activation domain. Patients with relapsed refractory MM who had received ≥ 3 prior lines of therapy, including a proteasome inhibitor and an immunomodulatory drug, were enrolled. Lymphodepletion with fludarabine and Cy was performed before injection of bb2121. Patients were administered bb2121 as a single infusion at doses of 50 × 10 6 , 150 × 10 6 , 450 × 10 6 , or 800 × 10 6 CAR-positive (CAR + ) T cells in the dose-escalation phase, and 150 × 10 6 to 450 × 10 6 CAR + T cells in the expansion phase. The response rate was 85%, including 15 patients (45%) with complete responses. Relapse was observed in 6 of the 15 patients who had a complete response. The median progression-free survival (PFS) was 11.8 months. All 16 responders (partial response or better) achieved MRD-negative status (≤ 10 -4 nucleated cells). Severe CRS (grade ≥ 3) occurred in 2 (6%) patients but resolved in 24 h. There were no grade 4 or 5 CRS events. One patient (3%) had grade 4 neurotoxicity. Nanjing Legend Biotech reported the safety and efficacy of LCAR-B38M, a dual-epitope binding CAR T cell therapy, in patients with relapsed/refractory MM [12] . This CAR recognizes two independent epitopes in BCMA. Seventeen patients were enrolled in the clinical trial. After CAR T cell infusion, 10 patients experienced mild CRS, 6 had severe but manageable CRS, and 1 died of a very severe toxic reaction. Among 17 cases, the overall response rate was 88.2%, with 13 achieving stringent complete response (sCR) and 2 reaching VGPR, while 1 was a non-responder. With a median follow-up of 417 days, 8 patients remained in sCR or VGPR, whereas 6 relapsed after sCR and 1 had progressive disease (PD) after VGPR. CAR T cell levels were high in most patients with stable response but low in 6 of 7 patients with relapse/PD. All of these trials clearly demonstrate the high efficacy of CAR T cells targeting BCMA against relapsed/refractory MM. The frequencies of severe CRS and neurotoxicity are similar to those observed in CD19 CAR T cell therapy. These results suggest that BCMA CAR T cell therapy is promising for relapsed/refractory MM. However, relapses associated with residual low-to-negative BCMA-expressing MM cells have been reported, necessitating the identification of additional targets.
Clinical trial of CAR T cell therapy targeting CD19
In most patients, MM plasma cells do not express CD19 [13] . However, recent reports showed that CD19 + cell populations contained clonal malignant cells [14, 15] , suggesting that these cells may represent myeloma-initiating cells (i.e., myeloma stem cells [16] ) that contribute to myeloma relapse. To eliminate myeloma-initiating cells, Garfall et al. at the University of Pennsylvania performed an early-phase clinical trial in which relapsed/refractory myeloma patients received CAR T cells against CD19 (CTL019) following salvage high-dose melphalan and autologous stem cell transplantation (ASCT) [17] . Patients were enrolled if they had relapsed/refractory MM, had previously undergone ASCT, and had a PFS of less than 1 year. After high-dose melphalan and ASCT, patients received CTL019. Most instances of toxicity were attributable to ASCT, and no severe CRS or neurotoxicity was observed. Two of 10 subjects exhibited significantly longer PFS after ASCT + CTL019 compared with prior ASCT (479 vs. 181 days, and 249 vs. 127 days, respectively). These results suggest that CAR T therapy targeting CD19 + myeloma-propagating cells following ASCT is beneficial, although trials in larger numbers of patients will be needed to confirm the results.
GRPC5D as a novel target for CAR T cell therapy against MM
Recently, 2 groups independently reported that the orphan G protein-coupled receptor, class C group 5 member D (GPRC5D), is specifically expressed in MM cells [18, 19] . A group identified GPRC5D-specific scFvs and used them to generate CAR T cells [18] . One of the GPRC5D-targeted CAR T cells eradicated MM and enabled long-term survival in mouse models. Murine cross-reactive CAR T cells did not cause alopecia or other signs of GPRC5D-mediated toxicity. Thus, GPRC5D CAR T cell therapy shows potential for the treatment of advanced MM irrespective of previous BCMAtargeted therapy.
Development of novel anti-MM CAR T cell therapy targeting activated integrin β7
Since many researchers have already performed extensive search for genes and proteins that are specifically expressed in MM cells, no MM-specific transcripts or proteins are likely to remain unidentified. However, if cancer-specific antigen epitopes are formed by post-translational events such as glycosylation, complex formation, or conformational changes, they may still remain unidentified. We screened for such antigen epitopes by thoroughly searching for MMspecific mAbs and identifying the antigens they react with. We established more than 10,000 clones of mAbs that react with MM cells. Then, we chose 504 mAbs that did not bind to normal peripheral blood mononuclear cells as candidates. Next, we stained bone marrow (BM) cells from MM patients with those candidate mAbs, analyzed on flow cytometry. Ultimately, we found that an antibody designated as MMG49 was specifically bound to MM cells, but not to CD45 + normal leukocytes in the BM. Next, we found that MMG49 bounds to integrin β7 using the expression cloning method. Interestingly, MMG49 did not bind to normal lymphocytes even though these cells definitely express integrin β7. We next showed that MMG49 binds only to the active conformation of integrin β7, but not to the inactive conformation. The MMG49 epitope is located in the N-terminal region of the β7 chain, which is predicted to be inaccessible in the resting integrin conformation but is exposed in the active conformation. Therefore, MMG49 abundantly binds to MM cells. Although integrin β7 is also expressed in normal lymphocytes at low levels, it adopts inactive conformation. Thus, MMG49 scarcely reacts with normal lymphocytes. In addition, integrin β7 is not expressed in vital organs other than hematopoietic systems. Furthermore, MMG49 antigen was also highly expressed in CD19-positive clonotypic B cells, which are candidates for MM precursor cells [16] , suggesting that the MMG49 antigen is a good therapeutic target for eradicating all MM clones. Taking these advantages of the MMG49 antigen, we established CAR T cells using the sequences of the variable regions of MMG49. MMG49 CAR T cells completely eliminated MM cells in vivo xenograft models without damaging normal hematopoietic cells. These results suggest that MMG49 CAR T cells targeting the activated conformation of integrin β7 is a promising for MM. Clinical trials will be performed soon. Importantly, these results provide the first clear evidence that that a conformation of a receptor protein can be a specific immunotherapeutic target [20] (Fig. 2) . 
